The historical rank and industry rank for Nova Eye Medical's FCF Margin % or its related term are showing as below:
ASX:EYE'
s FCF Margin % Range Over the Past 10 Years
Min: -114.77 Med: -21.03 Max: 29.27
Current: -16.1
During the past 13 years, the highest FCF Margin % of Nova Eye Medical was 29.27%. The lowest was -114.77%. And the median was -21.03%.
ASX:EYE's FCF Margin % is ranked worse than 69.57% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.03
vs ASX:EYE: -16.10
Nova Eye Medical FCF Margin % Related Terms
Nova Eye Medical FCF Margin % Historical Data
* Premium members only.
The historical data trend for Nova Eye Medical's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nova Eye Medical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Eye Medical (ASX:EYE) has a FCF Margin % of -14.92% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nova Eye Medical and its competitors. According to the industry distribution chart, Nova Eye Medical ranks #567 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 69.6%.
Is Nova Eye Medical's FCF Margin % too high?
Nova Eye Medical's current FCF Margin % is -14.92%. Based on the distribution chart, Nova Eye Medical ranks #567 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nova Eye Medical has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #567 out of 815 companies for FCF Margin %. This places Nova Eye Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nova Eye Medical and its competitors. Nova Eye Medical's current FCF Margin % is -14.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Based on GuruFocus' analysis, Nova Eye Medical (ASX:EYE) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.18, compared to a current price of A$0.11 — trading 41.7% below its estimated fair value. The current FCF Margin % is -14.92%. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nova Eye Medical (ASX:EYE), the current FCF Margin % is -14.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ASX:EYE) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of A$0.11 is trading 41.7% below its estimated GF Value™ of A$0.18.
GuruFocus considers Nova Eye Medical to be Possible Value Trap.
Key valuation signals for ASX:EYE:
FCF Margin %: -14.92%
GF Value™: A$0.18 vs. price of A$0.11 (41.7% below fair value)
No single metric tells the full story. See the ASX:EYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score
Get the complete analysis for ASX:EYE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EYE has been successfully added to your 
